Cargando…
Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128785/ https://www.ncbi.nlm.nih.gov/pubmed/33320291 http://dx.doi.org/10.1007/s00330-020-07592-0 |
| _version_ | 1783694167420960768 |
|---|---|
| author | Colagrande, S. Calistri, L. Campani, C. Dragoni, G. Lorini, C. Nardi, C. Castellani, A. Marra, F. |
| author_facet | Colagrande, S. Calistri, L. Campani, C. Dragoni, G. Lorini, C. Nardi, C. Castellani, A. Marra, F. |
| author_sort | Colagrande, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8128785 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81287852021-05-24 Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib Colagrande, S. Calistri, L. Campani, C. Dragoni, G. Lorini, C. Nardi, C. Castellani, A. Marra, F. Eur Radiol Correction Springer Berlin Heidelberg 2020-12-15 2021 /pmc/articles/PMC8128785/ /pubmed/33320291 http://dx.doi.org/10.1007/s00330-020-07592-0 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Colagrande, S. Calistri, L. Campani, C. Dragoni, G. Lorini, C. Nardi, C. Castellani, A. Marra, F. Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib |
| title | Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib |
| title_full | Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib |
| title_fullStr | Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib |
| title_full_unstemmed | Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib |
| title_short | Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib |
| title_sort | correction to: ct volume of enhancement of disease (ved) can predict the early response to treatment and overall survival in patients with advanced hcc treated with sorafenib |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128785/ https://www.ncbi.nlm.nih.gov/pubmed/33320291 http://dx.doi.org/10.1007/s00330-020-07592-0 |
| work_keys_str_mv | AT colagrandes correctiontoctvolumeofenhancementofdiseasevedcanpredicttheearlyresponsetotreatmentandoverallsurvivalinpatientswithadvancedhcctreatedwithsorafenib AT calistril correctiontoctvolumeofenhancementofdiseasevedcanpredicttheearlyresponsetotreatmentandoverallsurvivalinpatientswithadvancedhcctreatedwithsorafenib AT campanic correctiontoctvolumeofenhancementofdiseasevedcanpredicttheearlyresponsetotreatmentandoverallsurvivalinpatientswithadvancedhcctreatedwithsorafenib AT dragonig correctiontoctvolumeofenhancementofdiseasevedcanpredicttheearlyresponsetotreatmentandoverallsurvivalinpatientswithadvancedhcctreatedwithsorafenib AT lorinic correctiontoctvolumeofenhancementofdiseasevedcanpredicttheearlyresponsetotreatmentandoverallsurvivalinpatientswithadvancedhcctreatedwithsorafenib AT nardic correctiontoctvolumeofenhancementofdiseasevedcanpredicttheearlyresponsetotreatmentandoverallsurvivalinpatientswithadvancedhcctreatedwithsorafenib AT castellania correctiontoctvolumeofenhancementofdiseasevedcanpredicttheearlyresponsetotreatmentandoverallsurvivalinpatientswithadvancedhcctreatedwithsorafenib AT marraf correctiontoctvolumeofenhancementofdiseasevedcanpredicttheearlyresponsetotreatmentandoverallsurvivalinpatientswithadvancedhcctreatedwithsorafenib |